Lantus® / Toujeo®
Insulin Glargine is a long-acting insulin analog providing basal insulin coverage for approximately 24 hours with a relatively flat pharmacokinetic profile.
| Dosage Form | SC Injectable (Prefilled Pen / Vial) |
| Strength | 100 units/mL (Lantus); 300 units/mL (Toujeo) |
| Storage | Store at 2–8°C. After first use, store at room temperature for up to 28 days (Lantus) or 56 days (Toujeo). |
| Category | Diabetes & GLP-1 |
| Availability | Available for Transfer |
Type 1 diabetes mellitus; type 2 diabetes mellitus (basal insulin for glycemic control).
Long-acting insulin analog that forms microprecipitates at injection site due to low solubility at physiological pH, providing slow, prolonged absorption and relatively flat 24-hour activity.
Each Burrard Pharmaceuticals technology transfer package for Insulin Glargine includes comprehensive documentation and support:
Complete formulation with manufacturing parameters, excipient specifications, and process controls.
Validated methods for assay, impurities, dissolution, and stability-indicating analysis.
Market-ready regulatory dossier sections for a named territory, scoped per programme.
ICH-compliant stability studies (accelerated and long-term) with detailed protocols.
Scale-up procedures, batch records, equipment specifications, and in-process controls.
Direct advisory access to formulation scientists and regulatory specialists throughout transfer.
Scope and timing for the complete know-how package are confirmed in writing after a confidentiality agreement. Book a consultation to discuss your specific requirements.